Chemotherapy

Microbiology

Antibiotic Susceptibility Testing (Agar Disk Diffusion and Agar Dilution) of Clinical Isolates of Enterococcus faecalis and E. faecium: Comparison of Mueller-Hinton, Iso-Sensitest, and Wilkins-Chalgren Agar Media

Traub W.H. · Geipel U. · Leonhard B.

Author affiliations

Institut für Medizinische Mikrobiologie und Hygiene, Universität des Saarlandes, Homburg/Saar, Deutschland

Keywords: Agar disk diffusion test (Bauer-Kirby)Agar dilution testAntibiotic susceptibilityEnterococcus faecalisEnterococcus faeciumIso-Sensitest agarMinimal inhibitory concentrationsMueller-Hinton agarWilkins-Chalgren agar

Related Articles for ""
Chemotherapy 1998;44:217–229
https://doi.org/10.1159/000007118

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Microbiology

Published online: July 02, 1998
Issue release date: July – August

Number of Print Pages: 13
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Abstract

Forty-two isolates of Enterococcus faecalis and 56 isolates of Enterococcus faecium, including 8 vancomycin-resistant strains, were examined for comparative susceptibility to 27 antimicrobial drugs with the agar dilution method, employing Mueller-Hinton (MHA), Iso-Sensitest (ISTA), and Wilkins-Chalgren (WCA) agar. The Bauer-Kirby agar disk diffusion method was used to comparatively test 24 of the agents in parallel. The enterococci yielded better growth on ISTA and WCA. However, WCA completely antagonized co-trimoxazole and, though less, fosfomycin. Importantly, WCA slightly reduced the activities of teicoplanin (minimal inhibitory concentrations, MICs, raised up to twofold) and vancomycin (MICs raised two- to fourfold) against enterococci and staphylococcal quality control strains. Therefore, WCA was judged unsuitable for susceptibility testing of enterococci. For E. faecalis no discrepancies between agar dilution MICs and inhibition zone diameters were encountered with augmentin, ampicillin, ampicillin-sulbactam, chloramphenicol, mupirocin, oxacillin, teicoplanin, and co-trimoxazole. Overall, MHA yielded fewer very major (category I) and major (category II) discrepancies than ISTA. However, numerous minor (category III), slight (category IV), minimal (category V), and/or negligible (category VI) discrepanices were encountered with ciprofloxacin, doxycycline, erythromycin, fosfomycin, fusidic acid, meropenem, ofloxacin and rifampin. With respect to E. faecium, only cefotaxime, mupirocin, oxacillin, and teicoplanin yielded nondiscrepant results. Several very major (I) and major (II) discrepancies were observed with augmentin, ampicillin, ampicillin-sulbactam, doxycycline, fusidic acid, imipenem, and penicillin G. Minor discrepancies (categories III–VI) were particularly numerous with augmentin, chloramphenicol, ciprofloxacin, doxycycline, and piperacillin. The largest numbers of negligible (VI) discrepancies were noted with fosfomycin, fusidic acid, and ofloxacin. It is recommended to test one cephalosporin (cefuroxime or the like) in parallel for educational purposes and to exclude fosfomycin, fusidic acid, and rifampin from test batteries because of the wide scatter of test results. The large number of minimal (V) discrepancies of ciprofloxacin against E. faecalis, the numerous minor (III) and slight (IV) discrepancies of chloramphenicol against E. faecium, and the not insignificant number of very major (I) and minor (III) discrepancies observed with meropenem against isolates of E. faecalis necessitated proposals for new disk intermediate susceptibility criteria.



Related Articles:

References

  1. Hardie JM, Whiley RA: Classification and overview of the genera Streptococcus and Enterococcus. J Appl Microbiol 1997;83(suppl):1S–11S.
  2. Murray BE: The life and times of the Enterococcus. Clin Microbiol Rev 1990;3:46–65.
    External Resources
  3. Moellering RC: Emergence of Enterococcus as a significant pathogen. Rev Infect Dis 1992;14:1173–1178.
  4. Johnson AP: The pathogenicity of enterococci. J Antimicrob Chemother 1994;33:1083–1089.
    External Resources
  5. Wade JJ: Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997;16:113–119.
    External Resources
  6. Dunny GM: Pheromone-inducible conjugation in Enterococcus faecalis: Interbacterial and host-parasite chemical communication. J Bacteriol 1995;177:871–876.
    External Resources
  7. Leclercq R: Enterococci acquire new kinds of resistance. Clin Infect Dis 1997;24(suppl 1):S80–S84.
  8. Wade JJ, Uttley AHC: Resistant enterococci – Mechanisms, laboratory detection and control in hospitals. J Clin Pathol 1996;49:700–703.
    External Resources
  9. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, Lyons RW: An analysis of 110 serious enterococcal infections – Epidemiology, antibiotic susceptibility, and outcome. Medicine 1995;74:191–200.
    External Resources
  10. Wright GD, Ladak P: Overexpression and characterization of the chromosomal aminoglycoside 6′-N-acetyltransferase from Enterococcus faecium. Antimicrob Agents Chemother 1997;41:956–960.
    External Resources
  11. Murray BE, Mederski-Samoraj B: Transferable β-lactamase: A new mechanism for in vitro penicillin resistance in Streptococcus faecalis. J Clin Invest 1983;72:1168–1171.
    External Resources
  12. Okamoto R, Okubo T, Inoue M: Detection of genes regulating β-lactamase production in Enterococcus faecalis and Staphylococcus aureus. Antimicrob Agents Chemother 1996;40:2550–2554.
    External Resources
  13. Cercenado E, Vicente MF, Diaz MD, Sanchez-Carrillo C, Sanchez-Rubiales M: Characterization of clinical isolates of β-lactamase-negative highly ampicillin-resistant Enterococcus faecalis. Antimicrob Agents Chemother 1996;40:2420–2422.
    External Resources
  14. Ligozzi M, Pittaluga F, Fontana R: Modification of penicillin-binding protein 5 associated with high-level ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 1996;40:354–357.
    External Resources
  15. Kaufhold A, Klein R: Species identification and antibiotic susceptibility of enterococci isolated from clinical specimens of hospitalized patients. Zentralbl Baktertiol 1995;282:507–518.
  16. Tankovic J, Mahjoubi F, Courvalin P, Duval J, Leclercq R: Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother 1996;40:2558–2561.
    External Resources
  17. Lynch C, Courvalin P, Nikaido H: Active efflux of antimicrobial agents in wild-type strains of enterococci. Antimicrob Agents Chemother 1997;41:869–871.
    External Resources
  18. Ridenhour MB, Fletcher HM, Mortensen JE, Daneo-Moore L: A novel tetracycline-resistant determinant, tet(U), is encoded on the plasmid pKQ10 in Enterococcus faecium. Plasmid 1996;35:71–80.
    External Resources
  19. Leclercq R, Courvalin P: Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545–556.
    External Resources
  20. Arthur M, Reynolds PE, Depardieu F, Evers S, Dutka-Malen S, Quintiliani R Jr, Courvalin P: Mechanisms of glycopeptide resistance in enterococci. J Infect 1996;32:11–16.
    External Resources
  21. Struelens MJ: Multiple-resistant enterococci and Gram-negative bacteria: Tracking gene dissemination. Microb Drug Resist 1995;1:193–194.
    External Resources
  22. Coque TM, Tomayko JF, Ricke SC, Okhyusen PC, Murray BE: Vancomycin-resistant enterococci from nosocomial, community, and animal sources in the United States. Antimicrob Agents Chemother 1996;40:2605–2609.
    External Resources
  23. Jones RN, Marshall SA, Pfaller MA, Wilke WW, Hollis RJ, Erwin ME, Edmond MB, Wenzel RP, and the SCOPE Hospital Study Group: Nosocomial enterococcal blood stream infections in the SCOPE program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95–102.
    External Resources
  24. Davis JM, Huycke MM, Wells CL, Bohnen JMA, Gadaleta D, Fichtl RE, Barie PS: Surgical Infection Society position on vancomycin-resistant Enterococcus. Arch Surg 1996;131:1061–1068.
    External Resources
  25. Devera ME, Simmons RDL: Antibiotic-resistant enterococci and the changing face of surgical infections. Arch Surg 1996;131:338–342.
    External Resources
  26. George RC, Uttley AHC: Susceptibility of enterococci and epidemiology of enterococcal infection in the 1980s. Epidemiol Infect 1989;103:403–413.
    External Resources
  27. Uttley AHC, George RC, Naidoo J, Woodford N, Johnson AP, Collins CH, Morrison D, Gilfillan AJ, Fitch LE, Heptonstall J: High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 1989;103:173–181.
    External Resources
  28. Fraise AP: The treatment and control of vancomycin resistant enterococci. J Antimicrob Chemother 1996;38:753–756.
    External Resources
  29. Suppola JP, Volin L, Valtonen VV, Vaara M: Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996;23:694–697.
    External Resources
  30. Tonieporth NG, Roberts RB, John J, Hafner A, Riley LW: Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767–772.
    External Resources
  31. Papanicolaou GA, Meyers BR, Meyers J, Mendelson MH, Lou W, Emre S, Sheiner P, Miller C: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 1996;23:760–766.
    External Resources
  32. Bonten MJM, Gaillard CA, van Tiel FH, van der Geest S, Stobberingh EE: Colonization and infection with Enterococcus faecalis in intensive care units: The role of antimicrobial agents. Antimicrob Agents Chemother 1995;39:2783–2786.
    External Resources
  33. Klare I, Heier H, Claus H, Reissbrodt R, Witte W: VanA-mediated high level glycopeptide resistance in Enterococcus faecium from animal husbandry. FEMS Microbiol Lett 1995;125:165–172.
    External Resources
  34. McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR: Vancomycin-resistant enterococci outside the health-care setting: Prevalence, sources, and public health implications. Emerg Infect Dis 1997;3:311–317.
    External Resources
  35. Traub WH, Leonhard B: Simple combined agar strip test (CAST) for detection of enterococcal susceptibility to ampicillin, moderate- or high-level gentamicin resistance, and potential additive activity of ampicillin plus gentamicin. Chemotherapy 1993;39:82–87.
    External Resources
  36. Traub WH, Leonhard B, Bauer D: Enterococcus faecalis: In vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against high-level-gentamicin-resistant isolates. Chemotherapy 1993;39:248–253.
    External Resources
  37. Traub WH, Leonhard B, Bauer D: Enterococcus faecium: In vitro activity of antimicrobial drugs, single and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. Chemotherapy 1993;39:254–264.
    External Resources
  38. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Disk Susceptibility Tests, 5. NCCLS Document M2-A6. Villanova, NCCLS, 1997.
  39. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, ed 3. NCCLS Document M7-A3. Villanova, NCCLS, 1993.
  40. Facklam RR, Sahm DF: Enterococcus; in Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds): Manual of Clinical Microbiology, ed 6. Washington, American Society for Microbiology, 1995, pp 308–314.
  41. Bourgault A-M, Rosenblatt JE: Characterization of anaerobic gram-negative bacilli by using rapid slide tests for β-lactamase production. J Clin Microbiol 1979;9:654–656.
    External Resources
  42. Bauer AW, Kirby WMM, Sherris JC, Turck M: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966;45:493–496.
    External Resources
  43. Traub WH, Spohr M: Fosfomycin: Interpretation of inhibition zones obtained with the Bauer-Kirby agar disk diffusion susceptibility test. Chemotherapy 1983;29:208–212.
    External Resources
  44. Finlay JE, Miller LA, Poupard JA: Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997;41:1137–1139.
    External Resources
  45. Barry AL, Thornsberry C, Jones RN, Fuchs PC, Gavan TL, Gorbach EH: Reassessment of the ‘class’ concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. Am J Clin Pathol 1978;70:909–913.
    External Resources
  46. Traub WH, Kohl K-H, Spohr M: In vitro activity of three fluoroquinolones against enterococci and Pseudomonas aeruginosa: Modified categorization system for discrepant broth dilution and agar disk diffusion test results. Chemotherapy 1988;34:101–106.
    External Resources
  47. Traub WH, Leonhard B: Comparison of Wilkins-Chalgren medium supplemented with nicotinamide adenine dinucleotide and Haemophilus test medium for susceptibility testing of clinical Haemophilus isolates. Chemotherapy 1995;41:437–447.
    External Resources
  48. Kohnen PC, Patel R, Uhl JR, Garin KM, Hopkins MK, Wegener LT, Cockerill FR: Comparison of agar dilution, broth microdilution, E-test, disk diffusion, and automated Vitek methods for testing susceptibilities of Enterococcus spp. to vancomycin. J Clin Microbiol 1997;35:3258–3263.
    External Resources
  49. Landman D, Quale JM: Management of infections due to resistant enterococci: A review of therapeutic options. J Antimicrob Chemother 1997;40:161–170.
    External Resources
  50. Goodhart GL: In vivo v in vitro susceptibility of enterococcus to trimethoprim-sulfamethoxazole. A pitfall. JAMA 1984;252:2748–2749.
    External Resources
  51. Elsner H-A, Krüger W, Laufs R, Mack D: Septicemia due to susceptible Enterococcus faecalis despite prophylaxis with trimethoprim-sulfamethoxazole. Eur J Clin Microbiol Infect Dis 1997;16:620–622.
  52. Cormican MG, Biedenbach D, Jones RN: Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. Clin Microbiol Infect 1996;1:190–194.
    External Resources
  53. Endtz HP, van den Braak N, van Belkum A, Goessens WH, Kreft D, Stroebel AB, Verbrugh HA: Comparison of eight methods to detect vancomycin resistance in enterococci. J Clin Microbiol 1998;36:592–594.
    External Resources
  54. Herrera-Insua I, Jacques-Palaz K, Murray BE, Rakita RM: Intracellular activities of RP 59500 (quinupristin-dalfopristin) and sparfloxacin against Enterococcus faecium. Antimicrob Agents Chemother 1996;40:886–890.
    External Resources
  55. Chow JW, Davidson A, Sanford E, Zervos MJ: Superinfection with Enterococcus faecalis during quinupristin/dalfopristin therapy. Clin Infect Dis 1997;24:91–92.
    External Resources
  56. Chow JW, Donabedian SM, Zervos MJ: Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect 1997;24:90–91.
    External Resources
  57. Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC: In vitro activities of new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother 1996;40:1745–1747.
    External Resources
  58. Fraise AP, Brenwald N, Andrews JM, Wise R: In vitro activity of two glycylcyclins against enterococci resistant to other agents. J Antimicrob Chemother 1995;35:877–881.
    External Resources
  59. Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K: Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996;23:1020–1025.
    External Resources
  60. Chadwick PR, Oppenheim BA: Controlling glycopeptide-resistant enterococci. Clin Microbiol Infect 1997;3:7–11.
    External Resources
  61. Lai KK: Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996;156:2579–2584.
    External Resources
  62. Beezhold DW, Slaughter S, Hayden MK, Matushek M, Nathan C, Trenholme GM, Weinstein RA: Skin colonization with vancomycin-resistant enterococci among hospitalized patients with bacteremia. Clin Infect Dis 1997;24:704–706.
    External Resources
  63. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP: Vancomycin-resistant enterococcal bacteriemia: Natural history and attributable mortality. Clin Infect Dis 1996;23:1234–1239.
    External Resources
  64. Mekonen ET, Noskin GA, Hacek DM, Peterson LR: Successful treatment of persistent bacteremia due to vancomycin-resistant, ampicillin-resistant Enterococcus faecium. Microb Drug Resist 1995;1:249–253.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Microbiology

Published online: July 02, 1998
Issue release date: July – August

Number of Print Pages: 13
Number of Figures: 0
Number of Tables: 0

ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)

For additional information: https://www.karger.com/CHE

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1998, Vol.44, No. 4

July – August

Article

Recommend This
TOP